Innovative Tools and Perspectives in Cough Management: Cancer and Cough

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Cough is a common and debilitating symptom in lung cancer patients, affecting quality of life.
• Postoperative cough after lung resection (CAP) occurs in 25-50% of patients, often persisting beyond three months.
• Pulmonary rehabilitation and managing comorbidities are crucial for reducing cough incidence and severity.

Purpose of the Study:

• To review the evaluation and management of cough in lung cancer patients.
• To outline a stepwise treatment algorithm for both disease-related and postoperative cough.
• To discuss emerging therapies for refractory cough.

Main Methods:

• Narrative review of existing literature on cough in lung cancer.
• Analysis of risk factors for persistent postoperative cough.
• Evaluation of pharmacological and non-pharmacological interventions.

Main Results:

• A stepwise approach is recommended, starting with cancer treatment and supportive care.
• Simple demulcents and centrally/peripherally acting antitussives are first-line treatments.
• Neurokinin-1 (NK1) receptor antagonists, like aprepitant, show promise for refractory cough.

Conclusions:

• Cough management in lung cancer requires a comprehensive, stepwise approach.
• Early intervention with appropriate therapies can improve patient quality of life.
• Further high-quality trials are needed to validate emerging treatments and integrate them into standard care.